



## Helen Ljungdahl Round, Acarix President & CEO presents at Redeye Investor Forum

On May 4th at 14.40 Helen Ljungdahl Round, Acarix President & CEO, presents the latest developments in the company at the Redeye Investor Forum.

The presentation is live broadcast and can be followed at <https://www.redeye.se/events/871285/871285?tab=abouttheevent> where the replay and the presentations will be available afterwards.

### For more information contact:

Helen Ljungdahl Round, CEO, phone +1 267 809 1225, +46 730 770283, email [helen.round@acarix.com](mailto:helen.round@acarix.com)

Christian Lindholm, CFO, phone +46 705 118333, email [christian.lindholm@acarix.com](mailto:christian.lindholm@acarix.com)

### About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor® System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor System uses advanced acoustics and AI-technology to rule out CAD non-invasively in less than 10 minutes, with at least 96% certainty. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, [certifiedadviser@redeye.se](mailto:certifiedadviser@redeye.se)) is Certified Advisor of Acarix. For more information, please visit [www.acarix.com](http://www.acarix.com).

### Attachments

[Helen Ljungdahl Round, Acarix President & CEO presents at Redeye Investor Forum](#)